Melkersson-rosenthal syndrome G51.2

Chronic, systemic, granulomatous inflammation with the classic symptom triad: Cheilitis granulomatosa, facial paresis, lingua plicata. The full picture of the syndrome is rare, more frequent are differently pronounced minus variants. That of E. Melkersson and C. Rosenthal is now increasingly referred to under the broader term"orofacial granulomatosis" and more generally defined as "recurrent uni- or bilateral orofacial swelling with cranial nerve dysfunction or paresis".

The incidence of Melkersson-Rosenthal syndrome (MRS) in adults is reported to be 1:1250 (Ziem et al. 2000). In children, the full-blown MRS is rare.

Unknown, to be discussed: constitutional abnormality, hereditary or acquired disturbance of the autonomous defence system, inflammatory, possibly infection-allergic reactions to different antigens.

In about 30% of patients a familial occurrence is reported (Feng et al. 2014). An autosomal dominant inheritance is being discussed? Possibly the responsible gene is located on the chromosome 9p11.

The average age at manifestation is 14.1 years (Feng et al 2014).

The fully developed syndrome is only observed in a minority of patients in larger groups. Mono- and oligosymptomatic cases are the rule (>80%); they are also found as initial indicative manifestations.

Typical is a variable course of symptoms with circumscribed facial swelling, mostly lip swelling (initially recurrent, later persistent, usually unilateral) and facial nerve palsy. The changes are functionally and cosmetically disturbing for the patient, sometimes even painful.

• Circumscribed facial swelling:
  • Cheilitis granulomatosa (by far the most frequent partial manifestation of Melkersson-Rosenthal syndrome).
  • Further partial manifestations are described as circumscribed swellings of the cheeks, eyelids, forehead, palate, gingiva, tongue, (see also macroprosopitis), buttocks and anogenital region (see also granulomatous lymphangitis of the scrotum and penis)
• Facial nerve palsy (in 19.4% of cases): Mostly unilateral, in 25% of cases bilateral, always of the peripheral type.
• Lingua plicata in 54% of cases (normal population 13%). Assignment to cardinal symptoms is abandoned in recent years, has only indicator function.
• Minor symptoms: Due to their frequent and constant occurrence, they are of great importance in the diagnosis. They are found with decreasing frequency:
  • Crohn's disease (6.8%)
  • Migraine headaches (5.7%)
  • Paresthesia in the swelling area
  • Disturbances of tear secretion
  • Redness
  • Itching
  • Nausea/nausea
  • secretion disorders of the salivary glands or nasal mucosa
  • Swindle
  • Tingling
  • facial sweating
  • Acroparesthesia
  • Heat sensation
  • Globus feeling in the throat
  • acoustic sensations.
  • systemic lupus erythematosus (2.3%)

Erysipelas recidivans: Characteristic history with the early erysipelas tetrad (fever, redness, painful swelling, acute lymphadenopathy). Laboratory: signs of inflammation.

Herpes simplex recidivans: Typical interval-like course with signs of evident herpes simplex on the skin.

Furuncle of the upper lip: Acute course with circumscribed dolent swelling. The tip of the abscess is often purulent.

Macrocheilia of other cause: No variable course. Mostly evident underlying diseases such as exfoliative cheilitides etc.

Facial paresis of other cause: not combined with other partial symptoms of Melkersson-Rosenthal syndrome.

There are no approved therapies for this disease pattern so far. Unfortunately, there is a lack of reliable study results due to the rarity of the disease.

• Improvements can be achieved with clofazimine (e.g. Lamprene). Early use in particular improves the chances of success, initially 100 mg/day p.o. for 10 days, then alternating 100 mg 3-4 times/week for 6 months, repeated after a 3-month break if necessary. If there is no success, the dosage can be doubled.
• Alternative (better therapy modality): Fumaric acid ester (e.g. Fumaderm®) in the usual dosage. There are own personal experiences about this therapy approach as well as some published casuistics (G. Hauck 2017). Note: This therapy should be planned over a period of >12 months!
• Alternative: Permanent intake of non-steroidal anti-inflammatory drugs such as ibuprofen (e.g. Ibuprofen Heumann 400-800 mg/day).
• Alternative: Systemic glucocorticoids are often recommended, but in our experience show only moderate success. Prednisolone (e.g. Decortin H) initially 40-60 mg/day p.o. for 2-4 weeks, then slow dose reduction.
• Alternative: Omalizumab (Nettis E et al. 2018).
• Other methods: Multiple therapeutic modalities with chloroquine, diuretics, DADPS, acetylsalicylic acid, nicotinic acid amide, and others have been described with dubious success.

Thrustworthy, chronic, years-long, possibly life-long course. Quoad vitam good, quoad sanationem bad. Spontaneous remission possible.

1. Elias MK et al (2013) The Melkersson-Rosenthal syndrome: a retrospective study of biopsied cases. J Neurol 260:138-143
2. Feng S et al (2014) Melkersson-Rosenthal syndrome: a retrospective study of 44 patients. Acta Otolaryngol 134:977-981
3. Hauck G (2017) Fumaric acid ester therapy for Melkersson-Rosenthal syndrome. Act Dermatol 43: 459-460
4. Hornstein OP et al. (1987) Classification and clinical variation of Melkersson-Rosenthal syndrome (MRS). Z Hautkr 62: 1453-1475
5. Lüscher E (1949) syndrome from Melkersson-Rosenthal. Switzerland Med Weekly 79: 1-3
6. Melkersson E (1928) One case of recurrent social security benefits in connection with the epidemic of epidemic oedema. Hygiea, Stockholm 90: 737-741
7. Miescher G (1956) Cheilitis and pareitis granulomatosa without facial paresis in the presence of a scrotal lingua. Dermatologica 112: 536
8. Neuhofer J, Fritsch P (1984) Cheilitis granulomatosa (Melkersson-Rosenthal syndrome): treatment with clofazimine. dermatologist 35: 459-463
9. Nettis E et al(2018) A favorable response to omalizumab in a patient with cheilitis granulomatosa.
   J Allergy Clin Immunol Pract 6:1425-1426.
10. Rosenthal C (1931) Clinical hereditary biological contribution to constitutional pathology. Common occurrence of recurrent familial facial paralysis, angioneurotic facial edema and lingua plicata in families with arthritis. Z Total Neurol Psychiatry 131: 475-501
11. Stosiek N et al (1991) Melkersson-Rosenthal syndrome - Analysis of the course of 73 patients (1968-1990). Z Hautkr 66: 18-24
12. Sussman GL et al (1992) Melkersson-Rosenthal syndrome: clinical, pathologic, and therapeutic considerations. Ann Allergy 69: 187-194
13. Tausch I et al (1992) experiences with clofazimine therapy of Melkersson-Rosenthal syndrome. Dermatologist 43: 194-198
14. Shapiro M et al (2003) Melkersson-Rosenthal syndrome in the periocular area: a review of the literature and case report. Ann Plast Surgery 50: 644-648
15. van De Scheur MR et al (2003) Orofacial granulomatosis in a patient with Crohn's disease. J Am Acad Dermatol 49: 952-954
16. van der Waal RI et al (2001) Cheilitis granulomatosa. J Eur Acad Dermatol Venereol. 15: 519-523
17. Volz A et al (2010) Operative lip reduction plasty for therapy-resistant Cheilitis granulomatosa. JDDG 8: 303-305
18. Ziem PE et al(2000) Melkersson-Rosenthal syndrome in childhood: a challenge in differential diagnosis and treatment. Br J Dermatol 143: 860-863
19. Zimmer WM et al (1992) Orofacial manifestations of Melkersson-Rosenthal syndrome. A study of 42 patients and review of 220 cases from the literature. Oral Surg Oral Med Oral Catholic 74: 610-619